Table 1 Patient characteristics – demographics and disease history

From: Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies

Characteristic

HER2 positive n =100

HER2 negative n =22

Total population n =122

Median age, years

55.0

52.5

55.0

ECOG PS, n (%)

   

 0–1

97 (97)

19 (86)

116 (95)

 2

3 (3)

3 (14)

6 (5)

Disease stage, n (%)

   

 IIIB/IIIC (T4)

1 (1)

2 (9)

3 (2)

 IV

99 (99)

20 (91)

119 (98)

Prior anti-tumour therapy, n (%)

 Anthracyclines

100 (100)

22 (100)

122 (100)

 Taxanes

100 (100)

22 (100)

122 (100)

 Trastuzumab

100 (100)

0

100 (82)

Neoadjuvanta

2 (2)

0

2 (2)

Adjuvantb

4 (4)

0

4 (3)

Advanced/metastatic

98 (98)

0

98 (80)

No. of metastatic sites, n (%)

 ⩟3

43 (43)

9 (41)

52 (43)

 2

36 (36)

6 (27)

42 (34)

 1

21 (21)

7 (32)

28 (23)

Hormone receptor status, n (%)

 ER+ and/or PgR+

38 (38)

14 (64)

52 (43)

 ER− and PgR−

60 (60)

8 (36)

68 (56)

 Unknown (ER and/or PgR)

2 (2)

0

2 (2)

  1. Abbreviations: ECOG PS=European Cooperative Oncology Group Performance Status; ER=oestrogen; PgR=progesterone.
  2. aPatients received trastuzumab for neoadjuvant and advanced/metastatic setting.
  3. bTwo patients received trastuzumab for adjuvant and advanced/metastatic disease, two patients received in adjuvant setting only.
Back to article page